Investigating how PARP2 affects DNA repair and cancer treatment
The non-catalytic function of PARP2 in DNA repair and cancer therapy
This study is looking at how a protein called PARP2 affects blood health in people with certain cancer treatments, especially those with BRCA1/2 issues, to find better ways to help patients avoid serious side effects like anemia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10850707 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of PARP2, a protein involved in DNA repair, particularly in the context of cancer therapies that target BRCA1/2 deficiencies. The study uses mouse models to explore how mutations in PARP2 can lead to severe anemia and other blood-related issues, which are significant side effects of current cancer treatments. By examining these effects, the research aims to identify ways to improve treatment outcomes and reduce harmful side effects for patients undergoing therapy. The approach combines genetic engineering and cell biology techniques to uncover the underlying mechanisms of PARP2's function.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with BRCA1/2-deficient cancers, such as breast, ovarian, pancreatic, or prostate cancer.
Not a fit: Patients without BRCA1/2 deficiencies or those not undergoing PARP inhibitor therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective cancer treatments with fewer side effects for patients.
How similar studies have performed: Previous research has shown that targeting DNA repair mechanisms can improve cancer treatment outcomes, indicating potential success for this approach.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Zha, Shan — Columbia University Health Sciences
- Study coordinator: Zha, Shan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.